Monte Net Tangible Assets vs Accounts Payable Analysis
| GLUE Stock | USD 8.35 0.01 0.12% |
Monte Rosa financial indicator trend analysis is infinitely more than just investigating Monte Rosa Therapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Monte Rosa Therapeutics is a good investment. Please check the relationship between Monte Rosa Net Tangible Assets and its Accounts Payable accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Monte Rosa Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.
Net Tangible Assets vs Accounts Payable
Net Tangible Assets vs Accounts Payable Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Monte Rosa Therapeutics Net Tangible Assets account and Accounts Payable. At this time, the significance of the direction appears to have very strong relationship.
The correlation between Monte Rosa's Net Tangible Assets and Accounts Payable is 0.82. Overlapping area represents the amount of variation of Net Tangible Assets that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Monte Rosa Therapeutics, assuming nothing else is changed. The correlation between historical values of Monte Rosa's Net Tangible Assets and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Tangible Assets of Monte Rosa Therapeutics are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Net Tangible Assets i.e., Monte Rosa's Net Tangible Assets and Accounts Payable go up and down completely randomly.
Correlation Coefficient | 0.82 |
| Relationship Direction | Positive |
| Relationship Strength | Strong |
Net Tangible Assets
The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.Accounts Payable
An accounting item on the balance sheet that represents Monte Rosa obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Monte Rosa Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.Most indicators from Monte Rosa's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Monte Rosa Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Monte Rosa Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. As of November 22, 2024, Selling General Administrative is expected to decline to about 17.5 M. In addition to that, Tax Provision is expected to decline to about 185.9 K
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 1.1M | 3.8M | 4.3M | 4.5M | Depreciation And Amortization | 2.1M | 8.6M | 6.2M | 3.9M |
Monte Rosa fundamental ratios Correlations
Click cells to compare fundamentals
Monte Rosa Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Monte Rosa Therapeutics is a strong investment it is important to analyze Monte Rosa's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Monte Rosa's future performance. For an informed investment choice regarding Monte Stock, refer to the following important reports:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Monte Rosa Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Monte Rosa. If investors know Monte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Monte Rosa listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.78) | Revenue Per Share 0.221 | Return On Assets (0.28) | Return On Equity (0.61) |
The market value of Monte Rosa Therapeutics is measured differently than its book value, which is the value of Monte that is recorded on the company's balance sheet. Investors also form their own opinion of Monte Rosa's value that differs from its market value or its book value, called intrinsic value, which is Monte Rosa's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Monte Rosa's market value can be influenced by many factors that don't directly affect Monte Rosa's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Monte Rosa's value and its price as these two are different measures arrived at by different means. Investors typically determine if Monte Rosa is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Monte Rosa's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.